Patients with adverse mood effects from combined oral contraceptives have lower levels of prepulse inhibition than healthy controls

https://doi.org/10.1016/j.psyneuen.2008.01.007Get rights and content

Summary

Background

Negative mood symptoms remain one of the major reasons for discontinuation of oral contraceptive pills. The aim of this study was to compare acoustic startle response and prepulse inhibition (PPI) in women with different experience of oral contraceptive pills.

Methods

Thirty women currently on combined oral contraceptives (COCs) with no reports of adverse mood symptoms, 28 women currently on COCs and experiencing mood-related side effects from treatment, 27 women who had discontinued COC use for reasons other than adverse mood symptoms and 32 women who had discontinued COC use due to adverse mood effects were included.

The eyeblink component of the acoustic startle reflex was assessed using electromyographic measurements of musculus Orbicularis Oculi. Twenty pulse-alone trials (115 dB 40 ms broad-band white noise) and 40 prepulse–pulse trials were presented. The prepulse stimuli consisted of a 115 dB 40 ms noise burst preceded at a 100 ms interval by 20 ms prepulses that were 72, 74, 78, or 86 dB.

Results

Patients with adverse mood effects of COCs exhibited lower levels of PPI with 86 dB prepulse compared to COC users with no adverse effects of COCs (p<0.05). There was no difference in PPI between the two groups of prior COC users.

No significant difference was found between the groups regarding acoustic startle response.

Conclusion

Relative to COC users with no reports of adverse mood symptoms, subjects suffering from COC-induced negative mood displayed deficits in PPI of acoustic startle. The fact that there was no difference in PPI between the two groups of prior COC users indicates that deficient PPI is related to adverse mood effects caused by COCs.

Introduction

Among young women, combined oral contraceptive (COC) pills is the most common type of contraception with a user frequency in Sweden of almost 56% within the ages of 18–24 and 29% in ages 25–34 (Lewin et al., 1996). Ever since the introduction of COCs in the 1960s, one of the major reasons for discontinuing the use has been mood-related side effects, such as irritability, mood swings and depressive symptoms (Sanders et al., 2001; Oinonen and Mazmanian, 2002; Robinson et al., 2004). A recent prospective study reported that 7% of women on COC suffered from increased anxiety and 10% from depressive mood (Ernst et al., 2002). When assessed retrospectively, 16.3% of women reported oral contraceptive pill-related premenstrual mood deterioration (Joffe et al., 2003) and discontinuation rates due to adverse mood symptoms were of 14–21%, depending on age (Larsson et al., 1997). As many women refrain from using oral contraception because of adverse mood effects from COCs, it is important to elucidate the underlying pathophysiology for these changes in affect.

Despite the fact that COCs have been used for a long time and have been the subject of many studies, several issues related to adverse mood effects from COCs remain to be elucidated. These include the wide variety of progestin formulations used in COCs and the estrogenic or progestagenic profile of the preparation. Also, as subjects who had been prospectively defined as suffering from premenstrual syndrome (PMS) were more prone to report negative mood while on COCs (Cullberg, 1972), the prevalence of PMS or premenstrual dysphoric disorder (PMDD) prior to COC use could contribute to these adverse mood effects. Drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activities and drospirenone-containing COCs have been evaluated in several recent studies for treatment of PMDD with positive results (Freeman, 2002; Pearlstein et al., 2005). However, the possibility still remains that certain women with severe PMS, or subthreshold PMDD, are more likely to suffer from adverse mood effects during COC use than women with no cyclical mood changes. This might especially hold true for preparations containing levonorgestrel as these brands are more symptom provoking than COCs containing drospirenone (Sangthawan and Taneepanichskul, 2005).

The typical manifestation of PMDD is a recurrent constellation of physical and negative mood symptoms that emerge during the luteal phase and remit within a few days of the follicular phase (Halbreich et al., 2007). Symptoms are closely related to ovarian steroids as they occur only during ovulatory menstrual cycles (Hammarback and Backstrom, 1988; Hammarback et al., 1991; Sundstrom et al., 1999a) or during progesterone (Bjorn et al., 2003; Andreen et al., 2005) or estradiol administration (Schmidt et al., 1998). In addition to negative mood symptoms, objective manifestations of excitability, such as the acoustic startle response, are also affected in PMDD patients. The acoustic startle response is increased in an animal model of PMDD (Gulinello et al., 2003) and was recently also shown to be increased in PMDD patients (Epperson et al., 2007; Kask et al., 2007). The acoustic startle reflex (ASR) is a withdrawal reflex to sudden or noxious auditory stimuli which can be measured as an eyeblink in humans or as a whole-body response in laboratory animals (Davis, 1980). In addition, the acoustic startle response is also regulated by the agents thought to be critical to the etiology of premenstrual symptoms, notably progesterone fluctuations and underlying alterations in inhibitory neurotransmission via the GABAA receptor (Toufexis et al., 2004).

Sensorimotor gating can also be assessed by measuring prepulse inhibition (PPI) of the startle response using the PPI component of the ASR, which is thought to reflect an individual's ability to screen or “gate” sensory stimuli. The PPI paradigm uses a weak, non-startling acoustic stimulus (the prepulse) that typically decreases the reflexive eyeblink response (startle) produced by the subsequent startling target stimulus (the pulse). We have recently shown that women with PMDD have lower levels of PPI during the late luteal phase of the menstrual cycle compared to healthy controls (Kask et al., 2007). Ovarian steroids appear to influence PPI because women have lower levels of PPI than do men (Swerdlow et al., 1993) but only in the mid-luteal phase (Swerdlow et al., 1993; Jovanovic et al., 2004).

Given the similarities between premenstrual symptoms and adverse mood symptoms during COC use, the possibility of a similar underlying pathophysiology should be evaluated. As PMDD patients previously have been shown to have an increased acoustic startle response and deficient PPI, the primary aim of the current study was to compare startle response and PPI in patients with adverse mood effects of COCs and asymptomatic COC users. A secondary aim was to investigate startle response and PPI in former users of COCs, where discontinuation was, or was not, due to adverse mood effects.

Section snippets

Subjects

Two hundred and eighty-five women aged 19–38 with ongoing or past experience of COCs were screened for inclusion in the study. Patients were recruited from advertisement in newspapers and on advertising boards at Health Care Centers. Following a telephone screening, 117 women with different experiences of COCs were included in the study. Of these, 30 women were currently on COCs with no reports of adverse mood symptoms (COC-fine), 28 women were currently on COCs and experiencing mood-related

Results

Five subjects (one COC-fine, one COC-mood, one pCOC-fine and two subjects in the pCOC-mood group) were considered as non-responders. For technical reasons, the data from one COC-mood subject was lost. Hence, the study group consisted of 29 COC users without adverse mood symptoms (COC-fine), 26 COC users with adverse mood symptoms (COC-mood), 26 prior COC users without adverse mood symptoms (pCOC-fine), and 30 prior COC users with prior adverse mood symptoms (pCOC-mood). One patient in the

Discussion

The main finding of the present study was that patients with retrospective reports of adverse mood effects during ongoing treatment with combined oral contraceptives (COCs) displayed lower levels of prepulse inhibition (PPI) compared to asymptomatic COC users.

Our observation of lower levels of PPI in COC users with adverse mood symptoms correspond well with our prior study in PMDD patients, where PMDD patients displayed lower levels of PPI in the late luteal phase compared to healthy controls (

Role of funding source

This study was supported by grants from the Tore Nilsson Foundation, The Swedish Research Council project K2008-54X-20642-01-3, the Family Planning Foundation Uppsala, Magnus Bergwall Foundation and The Swedish Society of Medicine.

Conflict of interest

None of the authors have any conflicts to disclose.

Acknowledgments

Ulla Geifalk is acknowledged for her kind help with the steroid hormone analyses.

References (39)

  • I. Sundstrom et al.

    Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study

    Psychoneuroendocrinology

    (1997)
  • I. Sundstrom et al.

    Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects

    Neuropsychopharmacology

    (1997)
  • N.R. Swerdlow et al.

    Men are more inhibited than women by weak prepulses

    Biol. Psychiatry

    (1993)
  • N.R. Swerdlow et al.

    Changes in sensorimotor inhibition across the menstrual cycle: implications for neuropsychiatric disorders

    Biol. Psychiatry

    (1997)
  • M. Van den Buuse et al.

    Estrogen increases prepulse inhibition of acoustic startle in rats

    Eur. J. Pharmacol.

    (2001)
  • T. Bast et al.

    Hyperactivity, decreased startle reactivity, and disrupted prepulse inhibition following disinhibition of the rat ventral hippocampus by the gaba(a) receptor antagonist picrotoxin

    Psychopharmacology (Berl)

    (2001)
  • I. Bjorn et al.

    Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy

    J. Clin. Endocrinol. Metab.

    (2003)
  • J. Cullberg

    Mood changes and menstrual symptoms with different gestagen/estrogen combinations. A double blind comparison with a placebo

    Acta Psychiatr. Scand. Suppl.

    (1972)
  • C.N. Epperson et al.

    Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study

    Arch. Gen. Psychiatry

    (2002)
  • Cited by (16)

    • Behavioral characterization of co-exposure to cannabinoids and hormonal contraceptives in female rats

      2024, Progress in Neuro-Psychopharmacology and Biological Psychiatry
    • Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle—A double-blind, placebo-controlled randomized trial

      2017, Psychoneuroendocrinology
      Citation Excerpt :

      Peripheral markers of the serotonin system also appear to be altered in COC users (Weizman et al., 1988; Maes et al., 1992), although no difference in cortical 5HT2A binding between COC users and non-users has been demonstrated (Frokjaer et al., 2009). Finally, we have previously reported that women who experience adverse mood while on COC have deficient prepulse inhibition, a measure of sensorimotor gating with relevance for many anxiety disorders (Braff et al., 2001), in comparison with COC users who reported unchanged emotional well-being (Borgstrom et al., 2008). The findings of the present study were primarily driven by a subgroup of women who had a history suggestive of previous COC-induced mood symptoms.

    • Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill-A double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive

      2013, Psychoneuroendocrinology
      Citation Excerpt :

      Peripheral markers of the serotonin system also appear to be altered in COC users (Weizman et al., 1988; Maes et al., 1992), although a recent PET study found no difference in cortical 5HT2A binding between COC users and non-users (Frokjaer et al., 2009). Finally, we have previously reported that women who experience adverse mood while on COC have deficient prepulse inhibition, a measure of sensorimotor gating with relevance for many anxiety disorders (Braff et al., 2001), in comparison with COC users who reported unchanged emotional well-being (Borgstrom et al., 2008). To date, no studies using functional magnetic resonance imaging (fMRI) have been performed in COC users, why potential emotion-induced brain reactivity effects of COCs remain unexplored.

    • Natural and synthetic sex hormones: Effects on higher-order cognitive function and prepulse inhibition

      2013, Biological Psychology
      Citation Excerpt :

      Little is known about the effects of the OC on PPI. One study found that women with adverse mood-related side-effects from the OC had lower levels of PPI, compared to women with no adverse effects of the OC (Borgstrom et al., 2008). This study did not, however, statistically compare PPI in OC users with naturally cycling women or with men; this will be examined in the present study.

    View all citing articles on Scopus
    View full text